Novavax, Inc. (NVAX)
NASDAQ·Healthcare·Biotechnology
$7.96
-1.43%
Mkt Cap $1.33B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 26, 2026 | $89.85M | $147.14M | +63.77% | -$0.66 | $0.11 | +116.67% | — | — |
| Q4 2025 Nov 6, 2025 | $90.26M | $70.44M | -21.95% | -$1.08 | -$0.62 | +42.59% | — | — |
| Q3 2025 Aug 6, 2025 | $55.63M | $239.24M | +330.06% | -$0.07 | $0.62 | +985.71% | — | — |
| Q2 2025 May 8, 2025 | $343.85M | $666.65M | +93.88% | $0.71 | $2.93 | +312.68% | — | — |
| Q1 2025 Feb 27, 2025 | $84.38M | $88.31M | +4.66% | -$0.75 | -$0.51 | +32.00% | — | — |
| Q4 2024 Nov 12, 2024 | $90.92M | $84.51M | -7.05% | -$0.87 | -$0.76 | +12.64% | — | — |
| Q3 2024 Aug 8, 2024 | $458.57M | $415.48M | -9.40% | $1.64 | $0.99 | -39.63% | — | — |
| Q2 2024 May 10, 2024 | $101.16M | $93.86M | -7.22% | -$1.04 | -$1.05 | -0.96% | — | — |
| Q1 2024 Feb 28, 2024 | $321.97M | $291.34M | -9.51% | -$0.49 | -$1.44 | -193.88% | — | — |
| Q4 2023 Nov 9, 2023 | $321.65M | $22.06M | -93.14% | -$1.82 | -$1.26 | +30.77% | — | — |
| Q3 2023 Aug 8, 2023 | $239.16M | $424.43M | +77.47% | -$1.39 | $0.58 | +141.73% | — | — |
| Q2 2023 May 9, 2023 | $87.61M | $80.95M | -7.60% | -$3.38 | -$3.41 | -0.89% | — | — |
| Q1 2023 Feb 28, 2023 | $383.14M | $287.83M | -24.88% | -$0.92 | -$2.28 | -147.83% | — | — |
| Q4 2022 Nov 8, 2022 | $586.25M | $734.58M | +25.30% | $2.21 | -$2.15 | -197.29% | — | — |
| Q3 2022 Aug 8, 2022 | $863.68M | $185.93M | -78.47% | $5.51 | -$6.53 | -218.51% | — | — |
| Q2 2022 May 9, 2022 | $845.20M | $703.97M | -16.71% | $2.69 | $2.56 | -4.83% | — | — |
| Q1 2022 Feb 28, 2022 | $331.79M | $222.20M | -33.03% | -$1.43 | -$11.18 | -681.82% | — | — |
| Q4 2021 Nov 4, 2021 | $334.62M | $178.84M | -46.55% | -$4.04 | -$4.31 | -6.68% | — | — |
| Q3 2021 Aug 5, 2021 | $387.87M | $298.02M | -23.17% | -$3.76 | -$4.75 | -26.33% | — | — |
| Q2 2021 May 10, 2021 | $515.56M | $447.23M | -13.25% | -$2.65 | -$3.05 | -15.09% | — | — |